|
CA2564432A1
(en)
*
|
2004-04-27 |
2005-11-10 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Human anti-amyloid .beta. peptide antibody and fragment of said antibody
|
|
LT2769992T
(lt)
*
|
2006-10-02 |
2021-04-12 |
Regeneron Pharmaceuticals, Inc. |
Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
|
|
US7608693B2
(en)
*
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
ME02288B
(me)
|
2010-02-08 |
2016-02-20 |
Regeneron Pharma |
Miš sa zajedničkim lakim lancem
|
|
UA111731C2
(uk)
*
|
2010-10-06 |
2016-06-10 |
Рідженерон Фармасьютікалз, Інк. |
Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
|
|
BR112013008366B1
(pt)
|
2010-10-06 |
2022-02-08 |
Regeneron Pharmaceuticals, Inc |
Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações
|
|
PL3326648T3
(pl)
|
2011-01-28 |
2021-10-11 |
Sanofi Biotechnology |
Kompozycje farmaceutyczne zawierające ludzkie przeciwciała przeciwko PCSK9
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
IL273982B2
(en)
|
2011-08-05 |
2023-03-01 |
Regeneron Pharma |
Humanized mice possess a universal light chain
|
|
EP3536712B1
(en)
|
2011-09-16 |
2023-05-31 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
|
|
TW201333034A
(zh)
|
2011-12-22 |
2013-08-16 |
Astellas Pharma Inc |
新穎抗人類ｃｔｇｆ抗體
|
|
KR102345232B1
(ko)
|
2012-03-16 |
2021-12-30 |
리제너론 파마슈티칼스 인코포레이티드 |
pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
|
|
NZ629639A
(en)
|
2012-03-16 |
2017-03-31 |
Regeneron Pharma |
Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
|
|
TR201819492T4
(tr)
*
|
2012-08-21 |
2019-01-21 |
Regeneron Pharma |
Bir ıl-4r antagonisti uygulayarak astımı tedavi etmek veya önlemek için yöntemler.
|
|
WO2014031610A1
(en)
*
|
2012-08-21 |
2014-02-27 |
Sanofi |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
SG10201913822PA
(en)
*
|
2012-09-07 |
2020-03-30 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
SG11201501011WA
(en)
*
|
2012-09-07 |
2015-03-30 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI697334B
(zh)
*
|
2013-06-04 |
2020-07-01 |
美商再生元醫藥公司 |
藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
CN105517570B
(zh)
|
2013-06-21 |
2020-04-07 |
赛诺菲生物技术公司 |
通过施用il-4r拮抗剂治疗鼻息肉症的方法
|
|
TWI707694B
(zh)
*
|
2013-06-21 |
2020-10-21 |
法商賽諾菲生物技術公司 |
Ｉｌ-４ｒ拮抗劑用於製造治療鼻息肉症的藥物之用途
|
|
TWI682781B
(zh)
|
2013-07-11 |
2020-01-21 |
美商再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
WO2015073494A1
(en)
|
2013-11-12 |
2015-05-21 |
Sanofi |
Dosing regimens for use with pcsk9 inhibitors
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
CN106062004A
(zh)
*
|
2013-12-17 |
2016-10-26 |
科马布有限公司 |
人靶标
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
SG10201806025TA
(en)
*
|
2014-01-16 |
2018-08-30 |
Mario Umberto Francesco Mondelli |
Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
|
|
IL247290B
(en)
*
|
2014-02-21 |
2021-06-30 |
Sanofi Biotechnology |
Methods of treating or preventing asthma by adding an il-4r antagonist
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by adding an IL-4R antagonist
|
|
KR102695088B1
(ko)
|
2014-02-28 |
2024-08-16 |
리제너론 파아마슈티컬스, 인크. |
Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
|
|
KR20230158661A
(ko)
|
2014-03-21 |
2023-11-21 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 도메인 결합 단백질을 생산하는 비-인간 동물
|
|
KR20240017117A
(ko)
|
2014-07-16 |
2024-02-06 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
CA2967602A1
(en)
*
|
2014-11-14 |
2016-05-19 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
|
|
JP2018508224A
(ja)
|
2015-03-19 |
2018-03-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
抗原を結合する軽鎖可変領域を選択する非ヒト動物
|
|
RU2736732C2
(ru)
*
|
2015-04-02 |
2020-11-19 |
Интервет Интернэшнл Б.В. |
Антитела к альфа-рецептору собачьего интерлейкина-4
|
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
EA201890519A1
(ru)
|
2015-08-18 |
2018-07-31 |
Ридженерон Фармасьютикалз, Инк. |
Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
|
|
RU2753869C2
(ru)
|
2016-02-19 |
2021-08-24 |
Ридженерон Фармасьютикалз, Инк. |
Способы повышения эффективности вакцины путем введения антагониста il-4r
|
|
CN107474134B
(zh)
*
|
2016-06-08 |
2021-07-27 |
苏州康乃德生物医药有限公司 |
用于结合白细胞介素4受体的抗体
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
KR102462039B1
(ko)
|
2016-09-01 |
2022-11-02 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
|
|
KR20240146104A
(ko)
|
2016-09-22 |
2024-10-07 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
|
|
AU2017366873A1
(en)
|
2016-11-29 |
2019-06-13 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating PRLR positive breast cancer
|
|
TWI784988B
(zh)
|
2016-12-01 |
2022-12-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
|
EP3610041A1
(en)
|
2017-04-13 |
2020-02-19 |
Regeneron Pharmaceuticals, Inc. |
Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
|
|
CN114075269A
(zh)
|
2017-07-06 |
2022-02-22 |
菲仕兰坎皮纳荷兰私人有限公司 |
用于制备糖蛋白的细胞培养工艺
|
|
WO2019028367A1
(en)
|
2017-08-04 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
|
|
PT3515465T
(pt)
|
2017-08-18 |
2024-03-04 |
Regeneron Pharma |
Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
|
|
CA3079946A1
(en)
|
2017-10-30 |
2019-05-09 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
SG11202004380QA
(en)
|
2017-12-22 |
2020-06-29 |
Regeneron Pharma |
System and method for characterizing drug product impurities
|
|
KR20200115485A
(ko)
|
2018-01-31 |
2020-10-07 |
리제너론 파마슈티칼스 인코포레이티드 |
약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
|
|
CN110105451B
(zh)
*
|
2018-02-01 |
2020-12-18 |
北京凯因科技股份有限公司 |
IL-4Rα抗体及其用途
|
|
RU2758092C1
(ru)
*
|
2018-02-01 |
2021-10-26 |
Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. |
АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
MX2020008988A
(es)
|
2018-02-28 |
2020-09-28 |
Regeneron Pharma |
Sistemas y metodos para la identificacion de contaminantes virales.
|
|
EP4317959A3
(en)
|
2018-03-19 |
2024-03-27 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
CN112512571A
(zh)
|
2018-03-22 |
2021-03-16 |
表面肿瘤学公司 |
抗il-27抗体及其用途
|
|
CN108373505B
(zh)
*
|
2018-04-20 |
2019-08-20 |
北京智仁美博生物科技有限公司 |
抗il-4r抗体及其用途
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11292847B2
(en)
|
2018-05-13 |
2022-04-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an IL-4R inhibitor
|
|
CN110540590B
(zh)
*
|
2018-05-29 |
2023-08-18 |
康诺亚生物医药科技（成都）有限公司 |
一种自免疫抑制物的开发和应用
|
|
US11448651B2
(en)
*
|
2018-07-10 |
2022-09-20 |
Regeneron Pharmaceuticals, Inc. |
Modifying binding molecules to minimize pre-exisiting interactions
|
|
AU2019324403A1
(en)
|
2018-08-24 |
2021-01-28 |
Jiangsu Hengrui Medicine Co., Ltd. |
Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof
|
|
BR112020024296A2
(pt)
|
2018-08-27 |
2021-03-09 |
Regeneron Pharmaceuticals, Inc. |
Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína
|
|
JP7511542B2
(ja)
|
2018-08-30 |
2024-07-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質複合体を特徴づけるための方法
|
|
CN110872349A
(zh)
*
|
2018-09-04 |
2020-03-10 |
三生国健药业（上海）股份有限公司 |
结合人il-4r的抗体、其制备方法和用途
|
|
EP3878868B1
(en)
*
|
2018-11-09 |
2024-10-09 |
Ajou University Industry-Academic Cooperation Foundation |
Human antibody having high affinity to human il-4 receptor alpha, and use thereof
|
|
US11312778B2
(en)
|
2018-11-21 |
2022-04-26 |
Brian C. Machler |
Method for treating allergic contact dermatitis
|
|
CN111518211B
(zh)
*
|
2018-12-25 |
2022-06-21 |
江苏荃信生物医药股份有限公司 |
抗人白介素4受体α单克隆抗体的制药用途
|
|
EP3857237B1
(en)
|
2019-01-16 |
2023-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing disulfide bonds
|
|
AU2020231343A1
(en)
|
2019-03-06 |
2021-10-21 |
Regeneron Pharmaceuticals, Inc. |
IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
|
|
KR20210143246A
(ko)
|
2019-03-21 |
2021-11-26 |
리제너론 파아마슈티컬스, 인크. |
알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
|
|
US20200363400A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Competitive Ligand Binding Assays
|
|
CN112010977B
(zh)
*
|
2019-05-29 |
2022-04-26 |
山东博安生物技术股份有限公司 |
抗白介素4受体(il-4r)的抗体及其应用
|
|
CN110343666B
(zh)
*
|
2019-07-10 |
2023-05-30 |
通化东宝药业股份有限公司 |
一种cho细胞培养的补料培养基及其制备方法和应用
|
|
WO2021026203A1
(en)
|
2019-08-05 |
2021-02-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
|
|
CN114173816A
(zh)
|
2019-08-05 |
2022-03-11 |
瑞泽恩制药公司 |
通过施用il-4r拮抗剂治疗特应性皮炎的方法
|
|
US20220323937A1
(en)
|
2019-09-24 |
2022-10-13 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
|
CN111825766B
(zh)
|
2019-10-31 |
2021-05-11 |
上海洛启生物医药技术有限公司 |
抗il-4r单域抗体及其应用
|
|
KR20220104797A
(ko)
|
2019-11-25 |
2022-07-26 |
리제너론 파마슈티칼스 인코포레이티드 |
비수성 에멀전을 이용한 지속 방출 제형
|
|
CA3161037A1
(en)
|
2019-12-09 |
2021-06-17 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
WO2021150558A1
(en)
|
2020-01-21 |
2021-07-29 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
BR112022016345A2
(pt)
|
2020-02-21 |
2022-12-20 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Composição farmacêutica contendo anticorpo anti-il-4r e uso da mesma
|
|
AU2021228061A1
(en)
*
|
2020-02-27 |
2022-10-13 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Antibodies binding IL4R and uses thereof
|
|
AU2021244266A1
(en)
|
2020-03-27 |
2022-12-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an IL-4R antagonist
|
|
IL298257A
(en)
|
2020-05-22 |
2023-01-01 |
Regeneron Pharma |
Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
|
|
US20220064591A1
(en)
|
2020-08-31 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
MX2023003942A
(es)
|
2020-10-05 |
2023-06-02 |
Sanofi Biotechnology |
Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
|
|
CA3191141A1
(en)
|
2020-11-25 |
2022-06-02 |
Hunter Chen |
Sustained release formulations using non-aqueous membrane emulsification
|
|
JP2024500409A
(ja)
|
2020-12-17 |
2024-01-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質封入マイクロゲルの作製
|
|
US20240075158A1
(en)
*
|
2020-12-22 |
2024-03-07 |
Jiangsu Hengrui Pharmaceutical Co., Ltd. |
Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
|
|
KR20230130681A
(ko)
|
2021-01-08 |
2023-09-12 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
|
|
CN116761880A
(zh)
|
2021-01-20 |
2023-09-15 |
瑞泽恩制药公司 |
改进细胞培养物中的蛋白质滴度的方法
|
|
US20220404369A1
(en)
|
2021-03-03 |
2022-12-22 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
|
MX2023010794A
(es)
|
2021-03-26 |
2023-10-25 |
Regeneron Pharma |
Metodos y sistemas para el desarrollo de protocolos de mezcla.
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
CA3226781A1
(en)
|
2021-07-26 |
2023-02-02 |
Nikhil AMIN |
Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
|
|
WO2023017252A1
(en)
|
2021-08-10 |
2023-02-16 |
Kymab Limited |
Treatment of atopic dermatitis
|
|
EP4392450A1
(en)
|
2021-08-23 |
2024-07-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
KR20240053586A
(ko)
*
|
2021-08-26 |
2024-04-24 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
항il4r 항체의 의약 조성물 및 그의 사용
|
|
WO2023039457A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
|
|
EP4405390A1
(en)
|
2021-09-20 |
2024-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods of controlling antibody heterogeneity
|
|
MX2024003921A
(es)
|
2021-09-30 |
2024-04-22 |
Regeneron Pharma |
Variantes de la reticulocalbina-3 (rcn3) y tratamiento del asma con antagonistas del receptor alfa de la interleucina-4 (il4r).
|
|
US20230116199A1
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
|
EP4413359A1
(en)
|
2021-10-07 |
2024-08-14 |
Regeneron Pharmaceuticals, Inc. |
Ph meter calibration and correction
|
|
EP4419557A1
(en)
|
2021-10-20 |
2024-08-28 |
Sanofi Biotechnology |
Methods for treating prurigo nodularis by administering an il-4r antagonist
|
|
MX2024005090A
(es)
|
2021-10-26 |
2024-07-19 |
Regeneron Pharma |
Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
|
|
WO2023085978A1
(en)
*
|
2021-11-11 |
2023-05-19 |
Joint Stock Company «Biocad» |
Monoclonal antibody or antigen-binding fragment thereof that specifically binds to il-4ra, and use thereof
|
|
US20230272096A1
(en)
|
2021-11-11 |
2023-08-31 |
Regeneron Pharmaceuticals, Inc. |
Treatment Of Lung Disease Based Upon Stratification Of Polygenic Risk Score For Interleukin 33 (IL-33)
|
|
IL312714A
(en)
*
|
2021-11-18 |
2024-07-01 |
Twist Bioscience Corp |
DICKKOPF-1 variant antibodies and methods of use
|
|
EP4441249A1
(en)
|
2021-11-30 |
2024-10-09 |
Regeneron Pharmaceuticals, Inc. |
Treatment of lung disease based upon stratification of polygenic score relating to response to a therapeutic agent
|
|
KR20240135618A
(ko)
|
2021-12-30 |
2024-09-11 |
리제너론 파아마슈티컬스, 인크. |
Il-4/il-13 길항제를 투여하여 아토피 행진을 약화시키는 방법
|
|
TW202340252A
(zh)
|
2022-01-29 |
2023-10-16 |
大陸商上海盛迪醫藥有限公司 |
糖皮質激素的藥物偶聯物
|
|
WO2023167847A2
(en)
|
2022-03-02 |
2023-09-07 |
Regeneron Pharmaceuticals, Inc. |
Bioreactor for antibody production
|
|
WO2023177836A1
(en)
|
2022-03-18 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
|
WO2023191665A1
(en)
*
|
2022-03-31 |
2023-10-05 |
Milaboratory, Limited Liability Company |
ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
|
|
TW202421660A
(zh)
|
2022-07-08 |
2024-06-01 |
美商再生元醫藥公司 |
藉由投與il-4r拮抗劑來治療嗜伊紅性食道炎的方法
|
|
WO2024047021A1
(en)
|
2022-08-29 |
2024-03-07 |
Sanofi |
Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
|
|
KR20240038841A
(ko)
|
2022-09-16 |
2024-03-26 |
연세대학교 산학협력단 |
신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이의 용도
|
|
US20240141051A1
(en)
|
2022-11-01 |
2024-05-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hand and foot dermatitis by administering an il-4r antagonist
|
|
WO2024112935A1
(en)
|
2022-11-23 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for improving bone growth by administering an il-4r antagonist
|
|
US20240198253A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2024158880A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
US20240360232A1
(en)
|
2023-03-22 |
2024-10-31 |
Sanofi Biotechnology |
Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
|
|
US20240350626A1
(en)
|
2023-03-27 |
2024-10-24 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
|
|
WO2024199665A1
(en)
|
2023-03-30 |
2024-10-03 |
Sandoz Ag |
Stable composition comprising a high protein concentration
|
|
CN117924490B
(zh)
*
|
2023-12-22 |
2024-10-22 |
华润生物医药有限公司 |
抗il-4r抗体及其用途
|